BMJ Open · 6 authors, 4 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This paper describes the design and baseline characteristics of the ReLife study, a prospective cohort of 368 patients with localized renal cell cancer in the Netherlands. The study is designed to examine associations between lifestyle factors, body composition, biomarkers, and clinical outcomes, but no analytical results are reported yet.
The ReLife study is a multicentre prospective cohort study following 368 patients with newly diagnosed stages I–III renal cell cancer (RCC) recruited from 18 hospitals in the Netherlands. Data collection includes questionnaires on lifestyle and quality of life, accelerometer-measured physical activity, blood samples for biomarker analysis, and CT scans for body composition assessment at 3 months, 1 year, and 2 years post-treatment. Tumour samples and clinical data from medical records are also collected. The study has a 44% response rate; the mean age is 62.5±9.0 years, 70% are male, and 65% have stage I disease. The authors identify this as the first population-based prospective study on lifestyle and outcomes in localized RCC. Limitations include potential dropout, missing data, insufficient power for survival analyses, and the absence of RCC-specific quality of life measures. The study aims to inform personalized lifestyle advice.
